Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Ashvattha Therapeutics
company
About
Ashvattha Therapeutics is a biotechnology company that creates products that selectively target and treat human diseases.
- 11 - 50
Highlights
Details
- Last Funding Type
- Convertable Note
- Last Funding Money Raised
- $22M
- Industries
- Biotechnology,Health Care,Pharmaceutical,Therapeutics
- Founded date
- Jan 1, 2015
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Ashvattha Therapeutics creates products that selectively target and treat human diseases. Ashvattha enables precision targeting for therapeutics eliminating off-target toxicity, systemic side effects, and immunogenicity seen in other platforms. Ashvattha has a pipeline of nine therapeutics in neurology, oncology, and ophthalmology.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$29M
Ashvattha Therapeutics has raised a total of
$29M
in funding over 2 rounds. Their latest funding was raised on
May 31, 2020 from a Convertable Note round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| May 31, 2020 | Convertable Note | $22M | 2 |
Natural Capital
|
— | Detail |
| Mar 15, 2019 | Series A | $7M | 1 |
Natural Capital
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
2
2
Ashvattha Therapeutics is funded by 2 investors.
Natural Capital
and Zephyr Venture Partners
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Natural Capital
|
Yes | Convertable Note |
|
|
— | Convertable Note |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
